BioCryst Pharmaceuticals Files Q1 2025 10-Q
Ticker: BCRX · Form: 10-Q · Filed: May 6, 2025 · CIK: 882796
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals
Related Tickers: BCRX
TL;DR
BCRX Q1 2025 10-Q filed. Financials and ops update.
AI Summary
BioCryst Pharmaceuticals Inc. filed its 10-Q for the period ending March 31, 2025. The filing details the company's financial position and operational updates. Key financial data and disclosures relevant to investors are presented within this report.
Why It Matters
This filing provides investors with the latest financial performance and operational status of BioCryst Pharmaceuticals, crucial for understanding the company's trajectory and investment potential.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, BioCryst faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2025-03-31 — Period End Date (Quarterly financial reporting period)
- 2025-01-01 — Period Start Date (Quarterly financial reporting period)
Key Players & Entities
- BIOCRYST PHARMACEUTICALS INC (company) — Filer
- 20250331 (date) — Period of Report
- 20250506 (date) — Filing Date
- DURHAM (location) — Business Address City
FAQ
What is the reporting period for this 10-Q filing?
The Conformed Period of Report is 20250331, indicating the first quarter of 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on 20250506.
What is the company's primary business classification?
The Standard Industrial Classification is BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836].
Where is BioCryst Pharmaceuticals Inc. located?
The company's business address is in Durham, NC.
What is the fiscal year end for BioCryst Pharmaceuticals Inc.?
The fiscal year ends on 1231.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 6, 2025 regarding BIOCRYST PHARMACEUTICALS INC (BCRX).